Alnylam reports 60–64% mean mutant huntingtin reduction with brezosiran in Phase 1b, supporting target engagement in Huntington’s disease.
Written By: Malavatu Satvika, PharmD
Reviewed By: Pharmacally Editorial Team
Alnylam Pharmaceuticals has reported initial Phase 1b findings for brezosiran (ALN-HTT02), an investigational RNA interference (RNAi) therapeutic being developed in collaboration with Regeneron Pharmaceuticals for Huntington’s disease (HD). Following single ascending intrathecal doses, participants in the first five cohorts demonstrated dose-dependent reductions in cerebrospinal fluid (CSF) mutant huntingtin (mHTT). In the highest dose group evaluated, mean mHTT reduction reached 60–64% at month 3, while the maximum individual reduction was 83%.
The findings provide evidence of substantial target engagement and support further clinical development. However, reductions in a disease-associated biomarker do not establish that treatment slows Huntington’s disease progression, an important distinction for this early-stage programme.
Phase 1b Study Evaluates Safety and Target Engagement
The ongoing Phase 1b trial is randomized, double-blind and placebo-controlled, using a single-ascending-dose design to evaluate brezosiran’s safety, tolerability, pharmacokinetics and pharmacodynamics. It includes adults aged 25–70 years with genetically confirmed Huntington’s disease in HD-ISS Stage 2 or early Stage 3.
The reported findings cover 48 participants enrolled across the first five dose cohorts. A sixth cohort, planned to include 12 participants, was still enrolling and had not been evaluated at the time of the announcement. Dose escalation between successive cohorts was limited to increases of no more than threefold.
The study is ongoing in Canada, Germany and the United Kingdom. Its initial design primarily assesses safety and biological activity rather than definitive clinical efficacy. The announcement does not provide detailed cohort-level participant numbers, treatment allocation, exact dose levels or confidence intervals, limiting assessment of the precision and variability of the reported estimates.
Mutant Huntingtin Reduction Demonstrates Target Engagement
Dose-dependent CSF mHTT reductions were observed across the first five cohorts, with target engagement supported by two independent assays. In the highest dose group evaluated, mean reductions reached 60–64% at month 3. The maximum individual reduction of 83% represents an individual participant’s response rather than the cohort average.
These findings indicate that brezosiran can substantially reduce its intended molecular target following a single intrathecal administration. Nevertheless, CSF mHTT remains a pharmacodynamic biomarker, and its reduction cannot independently establish clinical benefit. The announcement does not report corresponding improvements in motor function, cognition, psychiatric symptoms or daily functioning.
Non-Allele-Selective HTT Lowering Includes HTT1a
Brezosiran uses Alnylam’s C16 conjugate platform for central nervous system delivery and is administered intrathecally. It targets exon 1 of huntingtin (HTT) messenger RNA, with the intention of reducing multiple HTT forms, including full-length mutant HTT and the shorter HTT1a transcript.
Brezosiran is designed for non-allele-selective HTT lowering, meaning its targeting approach can reduce both mutant and wild-type huntingtin. HTT1a is of particular mechanistic interest because evidence cited by the company suggests that this shorter transcript may contribute to disease pathology and progression.
Although this approach enables targeting of multiple HTT forms, wild-type HTT also performs important physiological functions. The extent of wild-type HTT suppression and its long-term consequences therefore remain relevant safety considerations. The initial clinical announcement does not separately quantify HTT1a reduction or establish additional clinical benefit from targeting this transcript.
Safety Monitoring Reflects Previous HTT-Lowering Challenges
Some participants had been followed for up to 12 months. Alnylam reported no dose-dependent increases in CSF inflammatory markers, CSF neurofilament light chain (NfL) or brain ventricular volume.
These measures are particularly relevant following earlier HTT-lowering trials. In Roche’s Phase 3 GENERATION HD1 study of tominersen, dose-regimen-dependent increases in ventricular volume and a transient elevation in CSF NfL were observed, alongside an unfavourable overall benefit-risk assessment that led to discontinuation of dosing in 2021. NfL is a biomarker of neuroaxonal injury, while ventricular volume provides an imaging-based measure of structural brain changes. These findings highlighted the importance of monitoring neurological injury and structural changes during HTT-lowering treatment.
Brezosiran’s initial safety observations are encouraging but do not establish long-term safety, exclude uncommon or delayed adverse events, or predict tolerability with repeated administration. The announcement does not provide a comprehensive adverse-event breakdown or dose-specific event rates.
Open-Label Extension and Pivotal Development
Eligible Phase 1b participants may transition into an open-label extension (OLE), with repeat brezosiran administration every six months for up to 36 months. According to the study design, participants initially assigned to placebo may receive a single open-label dose before entering the repeat-dose extension, while participants who previously received brezosiran may proceed to the OLE without an additional dose in the intervening open-label period. Participation remains optional and subject to eligibility.
The extension will assess long-term safety, sustained target engagement and exploratory measures of disease progression. However, its open-label design cannot provide the controlled comparison required to establish efficacy.
Huntington’s disease remains an area of substantial unmet medical need, with no approved disease-modifying therapies established to slow, halt or reverse its progression. Alnylam plans to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment, to determine whether brezosiran can translate its observed biomarker effects into meaningful clinical benefit.
The Phase 1b findings establish evidence of dose-dependent mHTT lowering following single intrathecal administration. However, the non-allele-selective mechanism, implications of wild-type HTT suppression, early-stage safety observations and absence of demonstrated clinical efficacy remain central to evaluating its therapeutic potential. The planned pivotal study will be critical in determining whether substantial huntingtin reduction can translate into slower disease progression.
Reference
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease, Alnylam, 23 October 2026
A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease, ClinicalTrials.gov ID NCT06585449
About the Writer
Malavatu Satvika (Linkedin) is a Pharm.D professional and aspiring healthcare medical writer with clinical exposure and research experience. Her interests include medical writing, drug safety, pharmaceutical research, and evidence-based healthcare communication. She has contributed to two research publications in pharmaceutical journals and has gained practical experience in prescription review, patient counselling, medication review, adverse drug reaction monitoring, drug information services, literature review, and clinical documentation through regular hospital training.
She has completed certifications in clinical research, ICH-GCP E6(R3), data management for clinical research, and congenital hypothyroidism. With a strong foundation in pharmacy, clinical practice, and scientific research, she aims to translate complex medical and pharmaceutical information into accurate, clear, and evidence-based healthcare content. She is also preparing to pursue a PhD and further develop her expertise in medical writing and pharmaceutical research.